Skip to main content
SpringerLink
Log in

Ondansetron Clinical Pharmacokinetics

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Ondansetron is a potent and highly selective serotonin 5-HT3-receptor antagonist which has demonstrated important antiemetic activity and good tolerability in the prevention of chemotherapy-induced nausea and vomiting.

Ondansetron is completely and rapidly absorbed from the gastrointestinal tract after oral administration, and does not accumulate with repeated oral administration. Owing to hepatic first-pass metabolism, its bioavailability is only about 60% compared with ondansetron administered by infusion over 15 minutes. Bioavailability is slightly increased when administered after a standard meal, and is not influenced by coadministration of antacids; a slightly enhanced bioavailability has been observed in patients with cancer. Since the time to reach peak concentration is 0.5 to 2 hours after oral ingestion, the drug should be administered at least 30 minutes before chemotherapy. Possible alternative ways of administration of ondansetron include intramuscular, subcutaneous and rectal administration, and oral controlled-release formulations.

Ondansetron is widely distributed (volume of distribution approximately 160L) and binds moderately (70 to 76%) to plasma proteins; the elimination half-life averages approximately 3.8 ± 1 hours. Clearance occurs by hepatic metabolism (95%) rather than renal excretion. Metabolites do not play a role in the activity of the drug, and there is no evidence of genetic polymorphic metabolism.

Although aging is associated with decreased clearance and increased bioavailability, dosage adjustments are not required for the elderly, and may be necessary only in patients with severe hepatic impairment. Chemotherapeutic agents do not seem to modify the pharmacokinetics of ondansetron.

There remains the question of whether control of emesis is related to systemic availability of ondansetron and, in consequence, the optimal dose and schedule of ondansetron is still to be identified with certainty.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities. Drug Saf 1993; 9: 410–28

    Article  PubMed  Google Scholar 

  2. Mackinnon JWM, Collin DT. The chemistry of ondansetron. Eur J Cancer Clin Oncol 1989; 25Suppl. 1: 61S

    Google Scholar 

  3. Colthup PV, Palmer JL. The determination in plasma and pharmacokinetics of ondansetron. Eur J Cancer Clin Oncol 1989; 25Suppl. 1:71S–4S

    Google Scholar 

  4. Wring SA, Rooney RM, Goddard CP, et al. A sensitive radioimmunoassay, combined with solid-phase extraction, for the sub-nanogram for ml determination of ondansetron in human plasma. J Pharm Biomed Anal 1994; 12: 361–71

    Article  PubMed  CAS  Google Scholar 

  5. Kelly JW, He L, Stewart JT. High-performance liquid chromatographic separation of ondansetron enantiomers in serum using a cellulose-derivatized stationary phase and solid-phase extraction. J Chromatogr 1993; 622: 291–5

    Article  PubMed  CAS  Google Scholar 

  6. Baber N, Palmer JL, Frazer NM, et al. Clinical pharmacology of ondansetron in postoperative nausea and vomiting. Eur J Anaesth 1992; 9Suppl. 6: 11S–8S

    Google Scholar 

  7. Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989; 25Suppl. 1: 21S–4S

    Google Scholar 

  8. Bryson JC, DeBussey SS, Brouwer KR, et al. Single and multiple oral dose pharmacokinetics (PK) of GR-C507/75 (GR38032): a novel compound effective in the treatment of chemotherapy-induced nausea (N) and vomiting (V) [abstract]. Proc Am Soc Clin Oncol 1988; 7: 69

    Google Scholar 

  9. Colthup PV, Felgate CC, Palmer JL, et al. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. J Pharm Sci 1991; 80: 868–71

    Article  PubMed  CAS  Google Scholar 

  10. Lazarus HM, Bryson JC, Lemon E, et al. Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR38032F) during multiple-day chemotherapy with cisplatin prior to antologous bone marrow transplantation. J Natl Cancer Inst 1989; 82: 1776–8

    Article  Google Scholar 

  11. Hsyu PH, Pritchard JF, Bozigian HP, et al. Oral ondansetron pharmacokinetics: the effect of chemotherapy. J Clin Pharmacol 1994; 34: 767–73

    PubMed  CAS  Google Scholar 

  12. Smith DB, Newlands ES, Rustin GJS. A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy. Cancer Chemother Pharmacol 1990; 25: 291–4

    Article  PubMed  CAS  Google Scholar 

  13. Pritchard JF, Bryson JC, Kernodle AE, et al. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther 1992; 51: 51–5

    Article  PubMed  CAS  Google Scholar 

  14. Pritchard JF, Wells CD. Relationship between ondansetron systemic exposure and antiemetic efficacy and safety in cancer patients receiving cisplatin. Pharmacology 1992; 45: 188–94

    Article  PubMed  CAS  Google Scholar 

  15. Haberer LJ, Gooding AE, Yin Y, et al. A dose-proportionality study of ondansetron administered as a single oral dose (tablet) to healthy male volunteers [abstract]. Pharm Res 1993; Suppl. 10: S–330

    Google Scholar 

  16. Bozigian HP, Pritchard JF, Godding AE, et al. Ondansetron absorption in adults: effect of dosage form, food and antacids. J Pharm Sci 1994; 83: 1011–3

    Article  PubMed  CAS  Google Scholar 

  17. Hsyu PH, Pritchard JF, Bozigian HP, et al. Comparison of the pharmacokinetics of an ondansetron solution (8mg) when administered intravenously, orally, to the colon, and to the rectum. Pharm Res 1994; 11: 156–9

    Article  PubMed  CAS  Google Scholar 

  18. Gan LS, Hsyu PH, Pritchard JF, et al. Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco-2 cell monolayers. Pharm Res 1993; 10: 1722–5

    Article  PubMed  CAS  Google Scholar 

  19. Palmer JL, Frazer NM, Keene ON, et al. Tolerability and pharmacokinetics of intramuscular ondansetron (OND) 4mg [abstract]. Clin Pharmacol Ther 1993; 53: 209

    Google Scholar 

  20. Mulvenna PM, Regnard CF. Subcutaneous infusion [letter]. Lancet 1992; 339: 1059

    Article  PubMed  CAS  Google Scholar 

  21. Philpot CR, Ven FAC. Ondansetron by subcutaneous infusion [letter]. Med J Australia 1993; 159: 213

    PubMed  CAS  Google Scholar 

  22. Pritchard JF. Ondansetron metabolism and pharmacokinetics. Semin Oncol 1992; 19Suppl. 10: 95–155

    Google Scholar 

  23. Simpson KH, Murphy P, Colthup PV, et al. Concentration of ondansetron in cerebrospinal fluid following drug dosing in volunteers. Psychopharmacology 1992; 109: 497–8

    Article  PubMed  CAS  Google Scholar 

  24. Saynor DA, Dixon CM. The metabolism of ondansetron. Eur J Cancer Clin Oncol 1989; 25Suppl. 1: 75S–7S

    Google Scholar 

  25. Fischer V, Vickers AEM, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994; 22: 269–74

    PubMed  CAS  Google Scholar 

  26. Ashfort EIL, Palmer JL, Bye A, et al. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br J Clin Pharmacol 1994; 37: 389–91

    Article  Google Scholar 

  27. Kennard D, Butcher M, Palmer J, et al. The anti-emetic efficacy, pharmacokinetics and safety of ondansetron in the elderly receiving cancer chemotherapy or radiotherapy. Eur J Cancer 1991; 27Suppl. 1: 27S

    Google Scholar 

  28. Lerman J, Spahr-Schopfer LA, Sikich N. Pharmacokinetics of intravenous ondansetron (5-HT3 antagonist) in healthy children [abstract]. Can J Anaesth 1993; 40: A24

    Article  Google Scholar 

  29. Bryson JC, Pritchard JF, Shurin S, et al. Efficacy, pharmacokinetics (PK) and safety of ondansetron (OND) in pediatric chemotherapy patients (pts) [abstract]. Clin Pharmacol Ther 1991; 49: 161

    Google Scholar 

  30. Blake JC, Palmer JL, Minton NA, et al. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. Br J Clin Pharmacol 1993; 35: 441–3

    Article  PubMed  CAS  Google Scholar 

  31. Figg WD, Dukes DE, Pritchard JF, et al. Ondansetron (OND) pharmacokinetics in chronic liver disease (LD) [abstract]. Clin Pharmacol Ther 1992; 51: 171

    Google Scholar 

  32. Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharm Ther 1989; 40: 439–74

    Article  CAS  Google Scholar 

  33. Pritchard JF, Powell JR. Circadian variations in the pharmacokinetics of ondansetron [abstract]. Clin Pharmacol Ther 1991; 49: 129

    Google Scholar 

  34. Bowman A, Allan SG, Leonard RCF, et al. The pharmacokinetics and antiemetic efficacy of the 5-HT3 antagonist GR38032F (GR) at different doses and schedules in cisplatinum (CP)-induced emesis [abstract]. Proc Eur Soc Med Oncol 1988; 250S

    Google Scholar 

  35. Grunberg SM, Groshen S, Robinson DC et al. Correlation of anti-emetic efficacy and plasma levels of ondansetron. Eur J Cancer 1990; 26: 879–82

    Article  PubMed  CAS  Google Scholar 

  36. Seynaeve C, de Mulder P, van Liessum P, et al. A positive correlation of the plasma ondansetron level with the control of cisplatin induced emesis [abstract]. Ann Oncol 1990; Suppl. 1: 112

    Google Scholar 

  37. Brouwer KR, Page R, Jarret J, et al. Concentration effect relationship for ondansetron in a cisplatin induced emesis model in beagle dogs [abstract]. Proc Am Soc Clin Oncol 1994; 13: 434

    Google Scholar 

  38. Marty M, d’Allens H, et le Groupe Multicentrique Francais: etude randomisée en double-insu comparant l’efficacité de l’ondansetron selon deux modes d’administration: injection unique et perfusion continue. Cahiers Cancer 1990; 2: 541–6

    Google Scholar 

  39. Seynaeve C, Schuller J, Buser K, et al. Comparison of the antiemetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 1992; 66:192–7

    Article  PubMed  CAS  Google Scholar 

  40. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10: 1969–75

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Division, Policlinico Hospital, 06122, Perugia, Italy

    Fausto Roila

  2. Department of Internal Medicine and Oncological Sciences, University of Perugia, Perugia, Italy

    Albano Del Favero

Authors
  1. Fausto Roila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albano Del Favero
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roila, F., Del Favero, A. Ondansetron Clinical Pharmacokinetics. Clin. Pharmacokinet. 29, 95–109 (1995). https://doi.org/10.2165/00003088-199529020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199529020-00004

Keywords

Search

Navigation